Ociperlimab clinical trials
Also written BGB-A1217 and WCD118.
How each study uses ociperlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 4 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ociperlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedPhase 3BeiGeneNCT04746924Written as Ociperlimab
- Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerCompletedPhase 2BeiGeneNCT05014815Written as Ociperlimab
- Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid TumorsCompletedPhase 1BeiGeneNCT04047862Written as Ociperlimab
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedPhase 2BeiGeneNCT04732494Written as Ociperlimab
- A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerTerminatedPhase 3BeiGeneNCT04866017Written as Ociperlimab
- Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast CancerWithdrawnPhase 2Novartis PharmaceuticalsNCT05809895Written as Ociperlimab
- Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.WithdrawnPhase 3Novartis PharmaceuticalsNCT05791097Written as Ociperlimab
Given beside what is tested · 6 — ociperlimab is usual care or a partner of the new treatment
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as Ociperlimab
- Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung CancerCompletedPhase 2BeiGeneNCT05577702Written as Ociperlimab
- Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedPhase 1/2BeiGeneNCT05267054Written as Ociperlimab
- AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical CancerCompletedPhase 2BeiGeneNCT04693234Written as Ociperlimab
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedPhase 2BeiGeneNCT04948697Written as Ociperlimab
- Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung CancerCompletedPhase 2BeiGeneNCT04952597Written as Ociperlimab
Codes
What other systems call ociperlimab · ClinicalTrials.gg INT015479
- UNII (FDA) 7JNY4KV3NKOCIPERLIMABOne source FDA
- NCI Thesaurus C170906OciperlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7JNY4KV3NK | OCIPERLIMAB | One source FDA |
| NCI Thesaurus | C170906 | Ociperlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.